A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
Status:
Recruiting
Trial end date:
2025-01-16
Target enrollment:
Participant gender:
Summary
Study TV50717-CNS-30081 is a 55-week study in which patients who have successfully completed
the parent study (Study TV50717-CNS-30080) may be eligible to enroll in this study.
The primary objective of this study is to evaluate the safety and tolerability of long-term
therapy with TEV-50717 in children and adolescents with DCP.
The secondary objective of this study is to evaluate the efficacy of long-term therapy with
TEV-50717 in reducing the severity of DCP.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.